Kristen Kluska

Q: How accurate are Kristen Kluska's stock ratings?

About 44% of Kristen's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, measured by 13Foresight from historical prices.

Q: How is Kristen ranked?

Kristen Kluska is ranked #2976 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Cantor Fitzgerald

Wall Street Analyst

★☆☆☆☆

#2976

on 13Foresight · ranked by our own returns

48%

Success Rate

+0.1%

Average Return

30 of 63 calls profitable · -8.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 48% of Kristen Kluska's ratings turned a profit when each position was held for 1 year — averaging +0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

134 Buy 21 Hold 0 Sell

Kristen's Stock Coverage 47 ratings · 2026-08-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PTCT PTC Therapeutics	Aug 12, 2026	BUY	Strong Buy +12.5% avg upside 29 analysts	$130.00 80.22% Upside	-1.6%	·
TSE:EPRX Eupraxia Pharmaceuticals	Aug 11, 2026	BUY	Strong Buy +140.4% avg upside 9 analysts	$26.50 183.02% Upside	·	·
TSHA Taysha Gene Therapies	Aug 11, 2026	BUY	Strong Buy +129.9% avg upside 21 analysts	$19.00 208.02% Upside	-12.6%	·
CDXS Codexis	Aug 11, 2026	BUY	Strong Buy +536.9% avg upside 13 analysts	$11.00 579.08% Upside	+8.1%	·
CLDX Celldex	Aug 06, 2026	BUY	Strong Buy -4.3% avg upside 28 analysts	$61.00 38.64% Upside	+0.1%	·
RNAC Cartesian Therapeutics	Aug 06, 2026	BUY	Strong Buy +261.7% avg upside 19 analysts	$16.00 81.83% Upside	+1.0%	·
ADMA ADMA Biologics	Aug 05, 2026	HOLD	Strong Buy +16.1% avg upside 15 analysts	$12.00 28.83% Upside	+2.3%	·
ZVRA Zevra Therapeutics	Aug 05, 2026	BUY	Strong Buy +95.5% avg upside 15 analysts	$25.00 122.59% Upside	+7.5%	·
SRPT Sarepta Therapeutics	Aug 05, 2026	HOLD	Buy +223.8% avg upside 49 analysts	$21.00 14.25% Upside	+13.6%	·
RIGL Rigel	Aug 04, 2026	HOLD	Strong Buy -40.3% avg upside 17 analysts	$43.00 5.63% Upside	+8.5%	·
RARE Ultragenyx Pharmaceutical	Aug 04, 2026	BUY	Strong Buy +151.9% avg upside 36 analysts	$96.00 262.75% Upside	+2.7%	·
CAPR Capricor Therapeutics	Jul 29, 2026	HOLD	Buy +206.4% avg upside 12 analysts	$3.50 19.17% Downside	+1.2%	·
DBVT DBV Technologies SA - American	Jul 16, 2026	BUY	Strong Buy +71.5% avg upside 15 analysts	$48.00 242.59% Upside	-5.8%	·
SUPN Supernus Pharmaceuticals	Jul 09, 2026	BUY	Strong Buy +19.0% avg upside 9 analysts	$67.00 40.56% Upside	-1.6%	·
AQST Aquestive Therapeutics	Jun 25, 2026	BUY	Strong Buy +110.4% avg upside 10 analysts	$11.00 153.37% Upside	-6.9%	·
SE:EGTX Egetis Therapeutics AB	Jun 25, 2026	BUY	Strong Buy +217.6% avg upside 1 analyst	$23.00 217.59% Upside	+21.7%	·
RNA Atrium Therapeutics, Inc.	Jun 18, 2026	BUY	Strong Buy +163.4% avg upside 5 analysts	$25.00 105.85% Upside	-2.6%	·
QURE uniQure	Jun 17, 2026	BUY	Strong Buy +26.1% avg upside 29 analysts	—	+1.0%	·
MNPR Monopar Therapeutics Inc	May 14, 2026	BUY	Strong Buy -8.0% avg upside 18 analysts	$109.00 2.31% Downside	+79.7%	·
SLDB Solid Biosciences	May 12, 2026	BUY	Strong Buy +74.4% avg upside 23 analysts	$16.00 78.03% Upside	+18.4%	·
IRON Disc Medicine	May 12, 2026	BUY	Strong Buy +8.9% avg upside 21 analysts	$125.00 55.60% Upside	+15.0%	·
MREO Mereo Biopharma Group Plc	May 12, 2026	BUY	Strong Buy +1190.6% avg upside 11 analysts	$3.00 920.78% Upside	+28.0%	·
LXEO Lexeo Therapeutics, Inc.	Mar 30, 2026	BUY	Strong Buy +292.1% avg upside 11 analysts	$19.00 290.90% Upside	-8.2%	·
FULC Fulcrum Therapeutics	Mar 19, 2026	BUY	Hold +138.7% avg upside 14 analysts	$24.00 557.53% Upside	-46.9%	·
SKYE Skye Bioscience	Mar 10, 2026	HOLD	Strong Buy +1799.0% avg upside 9 analysts	$2.00 263.56% Upside	-31.2%	·
ABEO Abeona Therapeutics	Feb 23, 2026	BUY	Strong Buy +168.3% avg upside 17 analysts	$28.00 340.57% Upside	+23.8%	·
PHAT Phathom Pharmaceuticals	Jan 13, 2026	BUY	Strong Buy +188.6% avg upside 14 analysts	$29.00 220.37% Upside	-38.7%	·
XFOR X4 Pharmaceuticals	Nov 21, 2025	BUY	Strong Buy +451.5% avg upside 16 analysts	$14.00 225.52% Upside	+12.5%	·
HUMA Humacyte	Jul 01, 2024	BUY	Strong Buy +1005.4% avg upside 11 analysts	$7.00 1012.84% Upside	-57.5%	·
IRD Opus Genetics	May 13, 2024	BUY	Strong Buy +178.4% avg upside 25 analysts	—	-42.9%	·
LCTX Lineage Therap	Feb 04, 2024	BUY	Strong Buy +420.5% avg upside 16 analysts	$6.00 455.61% Upside	-36.5%	·
OTLK Outlook Therapeutics	Aug 30, 2023	HOLD	Buy +932.2% avg upside 11 analysts	$20.00 2230.76% Upside	+36.6%	·
DRTS Alpha Tau Medical Ltd	Aug 28, 2023	BUY	Buy -3.9% avg upside 5 analysts	$23.00 56.29% Upside	-30.1%	·
ATNM Actinium Pharmaceuticals	Jun 28, 2023	BUY	Strong Buy +724.0% avg upside 11 analysts	$27.00 2983.23% Upside	+0.5%	·
DMRA Damora Therapeutics	Jun 26, 2023	BUY	Strong Buy -6.1% avg upside 20 analysts	$17.00 44.10% Downside	-80.6%	·
CMMB Chemomab Therapeutics	Jun 09, 2023	HOLD	Strong Buy +1328.5% avg upside 6 analysts	—	-41.7%	·
HEPA Hepion Pharmaceuticals	May 15, 2023	BUY	Strong Buy +69967.6% avg upside 9 analysts	$28.00 41942.13% Upside	·	·
EVLO Evelo Biosciences	Mar 16, 2023	HOLD	Buy +44999899.9% avg upside 5 analysts	$20.00 19999899.96% Upside	·	·
HTGMQ HTG Molecular Diagnostics	Mar 10, 2023	HOLD	Strong Buy +733333233.4% avg upside 6 analysts	—	·	·
PHGE BiomX	Mar 10, 2023	HOLD	Buy +16039.4% avg upside 4 analysts	—	·	·
IBIO Ibio	Dec 21, 2022	HOLD	Strong Buy +312.9% avg upside 11 analysts	$10.00 594.49% Upside	-84.8%	·
GLMD Galmed Pharmaceuticals	Aug 04, 2022	HOLD	Buy +4500.8% avg upside 13 analysts	$10.50 1881.09% Upside	·	·
ERNA Eterna Therapeutics	Dec 29, 2021	BUY	Strong Buy +1555.3% avg upside 4 analysts	$180.00 4047.47% Upside	·	·
OCGN Ocugen	Sep 28, 2021	HOLD	Strong Buy +583.5% avg upside 17 analysts	$4.00 190.92% Upside	-71.6%	·
MBIO Mustang Bio	May 12, 2021	BUY	Strong Buy +1038.0% avg upside 5 analysts	$10.00 1589.83% Upside	·	·
SCPX Scorpius Holdings	Mar 02, 2021	BUY	Strong Buy +1758233.3% avg upside 11 analysts	$22.00 2199900.08% Upside	·	·
EVGN Evogene	Nov 30, 2020	BUY	Strong Buy +1609.0% avg upside 6 analysts	$9.00 1309.72% Upside	·	·

🔒 42 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Kristen Kluska — Frequently Asked Questions

How accurate are Kristen Kluska's stock ratings?

Based on the calls 13Foresight could measure, about 44% of Kristen's ratings were profitable over a one-year hold, with an average return of -1.1% per rating, or -9.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Kristen ranked on 13Foresight?

Kristen Kluska is currently ranked #2976 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Kristen cover?

Kristen most recently has ratings on PTCT, TSE:EPRX, TSHA, CDXS, CLDX, RNAC, ADMA, ZVRA, SRPT, RIGL, RARE, CAPR and 35 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Kristen Kluska

Rating Distribution

Welcome to 13Foresight!